Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?
uniQure (QURE) reported earnings 30 days ago. What's next for the stock?
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.
uniQure Q2 Earnings Call Highlights
uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track to submit a biologics license application in the third quarter of 2026.
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.69 per share a year ago.
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from a technical perspective.
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
What made uniQure stock nearly double on Wednesday?
uniQure (QURE) stock is ripping higher this morning after the biopharmaceutical firm announced a major regulatory breakthrough with the FDA for its Huntington's disease gene therapy AMT-130. As investors cheered the disclosure, QURE pushed past its key moving averages (MAs) – and its relative strength index (RSI) climbed into the mid-80s, indicating intense buying pressure.
UniQure gets FDA green light to file for Huntington's gene therapy approval
Dutch drugmaker UniQure said on Wednesday the U.S. Food and Drug Administration has agreed that data from a mid-stage study could support an accelerated approval filing for its gene therapy to treat Huntington's disease.
